NCT04198766 2025-12-18Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)Inhibrx Biosciences, IncPhase 1/2 Active not recruiting296 enrolled
NCT03162536 2025-09-08ARQ 531-101ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Phase 1/2 Active not recruiting190 enrolled
NCT04544748 2024-03-06A Phase 1 Study of GNR-051 in Subjects With Advanced MalignanciesAO GENERIUMPhase 1 Active not recruiting48 enrolled